Kinnate Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Kinnate Biopharma

16/08/2021 22:40

* Kinnate Biopharma Inc  KNTE.OQ  reported a quarterly adjusted
loss of 49 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 43 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Kinnate Biopharma Inc's reported EPS for the quarter was a
loss of 49 cents​.
* The mean earnings estimate of analysts had fallen by
about 0.6% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Kinnate Biopharma Inc shares had fallen by 11.6% this
quarter and lost 48.2% so far this year.
* The company reported a quarterly loss of $21.45 million.
* Wall Street's median 12-month price target for Kinnate
Biopharma Inc is $51.00 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated August 16 at 09:40 p.m.  ​All
figures in US dollars unless otherwise stated